Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
IDrugs. 2003 Feb;6(2):159-63.

Ruboxistaurin (Eli Lilly).

Author information

  • 102-711 West 17th Avenue, Vancouver, BC V5Z 1V1, Canada. editor@greyowltutor.com

Abstract

Eli Lilly & Co is developing the protein kinase C (PKC)-b inhibitor ruboxistaurin, the lead compound from a series of 14-membered macrocycles, for the potential treatment of diabetic retinopathy, diabetic peripheral neuropathy and macular edema.

PMID:
12789620
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk